Tag: TRIL

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics (AXSM – Research Report) and Trillium Therapeutics (TRIL – Research Report).

Axsome Therapeutics (AXSM)

Mizuho Securities analyst Vamil Divan maintained a Buy rating on Axsome Therapeutics today and set a price target of $55.00. The company’s shares closed last Friday at $21.56, close to its 52-week low of $19.38.

According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.3% and a 47.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and Arcutis Biotherapeutics.

Axsome Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $96.67, representing a 348.4% upside. In a report issued on August 9, Berenberg Bank also maintained a Buy rating on the stock with a $112.00 price target.

See today’s analyst top recommended stocks >>

Trillium Therapeutics (TRIL)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright downgraded Trillium Therapeutics to Hold, with a price target of $18.50. The company’s shares closed last Friday at $6.09, close to its 52-week low of $5.80.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 22.7% and a 42.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Janux Therapeutics Inc, and Corvus Pharmaceuticals.

Trillium Therapeutics has an analyst consensus of Hold, with a price target consensus of $18.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AXSM:

• Nokia Expands 5G Footprint with A1 Telekom into new markets
• JD.com Posts Upbeat Q2 Results; Analysts Remain Bullish
• Timken Snaps up Intelligent Machine Solutions
• Heartland Declares Special Dividend; Approves Share Buyback Plan
• Jefferies Thinks Sigilon Therapeutics’ Stock is Going to Recover

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Trillium Therapeutics (TRIL – Research Report), with a price target of $22.00. The company’s shares closed last Friday at $6.23, close to its 52-week low of $5.99.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 24.1% and a 43.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Janux Therapeutics Inc, and Corvus Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trillium Therapeutics with a $22.00 average price target.

See today’s analyst top recommended stocks >>

Based on Trillium Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.86 million. In comparison, last year the company had a GAAP net loss of $16.3 million.

Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRIL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Read More on TRIL:

• Analysts’ Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Biohaven Pharmaceutical Holding Co (BHVN)
• Broadridge Financial Solutions’ Earnings and Risk Factors
• Beam Global (BEEM) Receives a Rating Update from a Top Analyst
• H.C. Wainwright Thinks SenesTech’s Stock is Going to Recover
• Ion Geophysical (IO) Gets a Buy Rating from H.C. Wainwright